Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

NCT ID: NCT00371683

Last Updated: 2015-12-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

3608 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis \[DVT\]) and lung (pulmonary embolism \[PE\]) that sometimes occur after knee replacement surgery and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deep Vein Thrombosis Pulmonary Embolism

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A1

\+ placebo

Group Type ACTIVE_COMPARATOR

Enoxaparin + Placebo

Intervention Type DRUG

Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period

A2

\+ placebo

Group Type EXPERIMENTAL

Apixaban + Placebo

Intervention Type DRUG

Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enoxaparin + Placebo

Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period

Intervention Type DRUG

Apixaban + Placebo

Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lovenox®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and non-pregnant, non-breastfeeding women
* 18 years or older
* Scheduled for knee replacement surgery

Exclusion Criteria

* hereditary or acquired bleeding disorders
* clotting disorders
* bleeding or high risk for bleeding
* drugs that affect bleeding or coagulation
* need for ongoing parenteral or oral anticoagulation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Capstone Clinical Trials, Inc

Birmingham, Alabama, United States

Site Status

Capstone Clinical Trials, Inc

Birmingham, Alabama, United States

Site Status

West Alabama Research, Inc.

Tuscaloosa, Alabama, United States

Site Status

Martin Bowen Hefley Orthopedics

Little Rock, Arkansas, United States

Site Status

Colorado Orthopedic Consultants, Pc

Aurora, Colorado, United States

Site Status

Colorado Joint Replacement

Denver, Colorado, United States

Site Status

Jdpmedical Research

Denver, Colorado, United States

Site Status

Orhtopaedic Physicians Of Colorado, P.C.

Englewood, Colorado, United States

Site Status

Orthopedics Assocs Of Hartford

Hartford, Connecticut, United States

Site Status

Anthony S. Unger, Md

Washington D.C., District of Columbia, United States

Site Status

Bay Pines Va Medical Center

Bay Pines, Florida, United States

Site Status

Pab Clinical Research

Brandon, Florida, United States

Site Status

Jacksonville Center For Clinical Research

Jacksonville, Florida, United States

Site Status

Mark W. Hollmann, Md

Orange City, Florida, United States

Site Status

Jewett Orthopaedic Clinic

Winter Park, Florida, United States

Site Status

Atlanta Knee And Sports Medicine

Decatur, Georgia, United States

Site Status

Americana Orthopedics

Boise, Idaho, United States

Site Status

Intermountain Orthopaedics

Boise, Idaho, United States

Site Status

Bluegrass Orthopaedics/Bmr

Lexington, Kentucky, United States

Site Status

Charleston Orthopaedic Assocs.

Charleston, South Carolina, United States

Site Status

Kelsey Seybold Clinic

Houston, Texas, United States

Site Status

Bone & Joint Clinic Of Houston

Houston, Texas, United States

Site Status

Gill Orthopedic Center

Lubbock, Texas, United States

Site Status

Robert R. King, Md

Lubbock, Texas, United States

Site Status

Unlimited Research

San Antonio, Texas, United States

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Buenos Aires, Buenos Aires, Argentina

Site Status

Local Institution

Capital Federal, Buenos Aires, Argentina

Site Status

Local Institution

Capital Federal, Buenos Aires, Argentina

Site Status

Local Institution

Córdoba, Córdoba Province, Argentina

Site Status

Local Institution

Garran, Australian Capital Territory, Australia

Site Status

Local Institution

Camperdown, New South Wales, Australia

Site Status

Local Institution

Caringbah, New South Wales, Australia

Site Status

Local Institution

Lismore, New South Wales, Australia

Site Status

Local Institution

Gold Coast, Queensland, Australia

Site Status

Local Institution

Adelaide, South Australia, Australia

Site Status

Local Institution

Bedford Park, South Australia, Australia

Site Status

Local Institution

Box Hill, Victoria, Australia

Site Status

Local Institution

Windsor, Victoria, Australia

Site Status

Local Institution

Perth, Western Australia, Australia

Site Status

Local Institution

Curitiba, Paraná, Brazil

Site Status

Local Institution

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Local Institution

Porto Alegre, Rs, Rio Grande do Sul, Brazil

Site Status

Local Institution

Campinas, São Paulo, Brazil

Site Status

Local Institution

São Paulo, São Paulo, Brazil

Site Status

Local Institution

Edmonton, Alberta, Canada

Site Status

Local Institution

Ajax, Ontario, Canada

Site Status

Local Institution

Burlington, Ontario, Canada

Site Status

Local Institution

Cambridge, Ontario, Canada

Site Status

Local Institution

Chatham, Ontario, Canada

Site Status

Local Institution

Dartmouth, Ontario, Canada

Site Status

Local Institution

Guelph, Ontario, Canada

Site Status

Local Institution

Lindsay, Ontario, Canada

Site Status

Local Institution

Newmarket, Ontario, Canada

Site Status

Local Institution

Niagara Falls, Ontario, Canada

Site Status

Local Institution

Sarnia, Ontario, Canada

Site Status

Local Institution

Scarborough Village, Ontario, Canada

Site Status

Local Institution

Scarborough Village, Ontario, Canada

Site Status

Local Institution

St. Catharines, Ontario, Canada

Site Status

Local Institution

Stratford, Ontario, Canada

Site Status

Local Institution

Waterloo, Ontario, Canada

Site Status

Local Institution

Windsor, Ontario, Canada

Site Status

Local Institution

Charlottetown, Prince Edward Island, Canada

Site Status

Local Institution

Montreal, Quebec, Canada

Site Status

Local Institution

Québec, Quebec, Canada

Site Status

Local Institution

Hørsholm, , Denmark

Site Status

Local Institution

Kopenhamn S, , Denmark

Site Status

Local Institution

Kecskemét, , Hungary

Site Status

Local Institution

Székesfehérvár, , Hungary

Site Status

Local Institution

Szolnok, , Hungary

Site Status

Local Institution

Afula, , Israel

Site Status

Local Institution

Beersheba, , Israel

Site Status

Local Institution

Haifa, , Israel

Site Status

Local Institution

Holon, , Israel

Site Status

Local Institution

Kfar Saba, , Israel

Site Status

Local Institution

Petah Tikva, , Israel

Site Status

Local Institution

Rehovot, , Israel

Site Status

Local Institution

Ẕerifin, , Israel

Site Status

Local Institution

Chihuahua City, Chihuahua, Mexico

Site Status

Local Institution

Tijuana, Estado de Baja California, Mexico

Site Status

Local Institution

Guadalajara, Jalisco, Mexico

Site Status

Local Institution

Df, Mexico City, Mexico

Site Status

Local Institution

Df, Mexico City, Mexico

Site Status

Local Institution

Df, Mexico City, Mexico

Site Status

Local Institution

Monterrey, Nuevo León, Mexico

Site Status

Local Institution

Monterrey, Nuevo León, Mexico

Site Status

Local Institution

Ciudad Madero, Tamaulipas, Mexico

Site Status

Local Institution

Jalapa, Veracruz, Mexico

Site Status

Local Institution

Mérida, Yucatán, Mexico

Site Status

Local Institution

Mérida, Yucatán, Mexico

Site Status

Local Institution

Bialystok, , Poland

Site Status

Local Institution

Krakow, , Poland

Site Status

Local Institution

Lodz, , Poland

Site Status

Local Institution

Lublin, , Poland

Site Status

Local Institution

Szczecin, , Poland

Site Status

Local Institution

Warsaw, , Poland

Site Status

Local Institution

Warsaw, , Poland

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Samara, , Russia

Site Status

Local Institution

Gothenburg, , Sweden

Site Status

Local Institution

Adana, , Turkey (Türkiye)

Site Status

Local Institution

Bursa, , Turkey (Türkiye)

Site Status

Local Institution

Mersin, , Turkey (Türkiye)

Site Status

Local Institution

Trabzon, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway United States Argentina Australia Brazil Canada Denmark Hungary Israel Mexico Poland Russia Sweden Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16.

Reference Type DERIVED
PMID: 35570249 (View on PubMed)

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604. doi: 10.1056/NEJMoa0810773.

Reference Type DERIVED
PMID: 19657123 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CV185-034

Identifier Type: -

Identifier Source: org_study_id